View source for 20240021315. IN VITRO METHOD FOR PREDICTING THE RISK OF DEVELOPING A BREAST LATE EFFECT AFTER RADIOTHERAPY simplified abstract (INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER)

=IN VITRO METHOD FOR PREDICTING THE RISK OF DEVELOPING A BREAST LATE EFFECT AFTER RADIOTHERAPY=


==Organization Name==

[[:Category:INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER|INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER]]


[[Category:INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER]]

==Inventor(s)==

[[:Category:David Azria of Fontanes (FR)|David Azria of Fontanes (FR)]][[Category:David Azria of Fontanes (FR)]]

[[:Category:Sophie Gourgou of Jacou (FR)|Sophie Gourgou of Jacou (FR)]][[Category:Sophie Gourgou of Jacou (FR)]]

==IN VITRO METHOD FOR PREDICTING THE RISK OF DEVELOPING A BREAST LATE EFFECT AFTER RADIOTHERAPY - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240021315 titled 'IN VITRO METHOD FOR PREDICTING THE RISK OF DEVELOPING A BREAST LATE EFFECT AFTER RADIOTHERAPY

==Simplified Explanation==

The present invention is a new diagnosis method and calculator for predicting the risk of developing a breast late effect (BLE) in a subject after radiotherapy (RT). The BLE is defined as atrophic skin, telangiectasia, induration (fibrosis), necrosis or ulceration. The method uses radiation-induced late effect using T-lymphocyte apoptosis (RILA) and clinical parameters. The invention also includes diagnosis kits for implementing the method and a nomogram.

* The invention is a new diagnosis method and calculator for predicting the risk of developing a breast late effect (BLE) after radiotherapy (RT).
* The BLE is defined as atrophic skin, telangiectasia, induration (fibrosis), necrosis or ulceration.
* The method uses radiation-induced late effect using T-lymphocyte apoptosis (RILA) and clinical parameters.
* The invention includes diagnosis kits for implementing the method.
* The invention also includes a nomogram.

Potential applications of this technology:

* Predicting the risk of developing a breast late effect (BLE) in patients who have undergone radiotherapy.
* Assisting healthcare professionals in determining the appropriate treatment plan for patients based on their risk of developing a BLE.
* Improving patient outcomes by identifying individuals who are at a higher risk of developing a BLE and providing them with targeted interventions or preventive measures.

Problems solved by this technology:

* Currently, there is no reliable method for predicting the risk of developing a breast late effect (BLE) after radiotherapy.
* Healthcare professionals often have to rely on subjective assessments and clinical observations to determine the risk of BLE, which can be inaccurate and inconsistent.
* This technology provides a more objective and accurate method for assessing the risk of BLE, allowing for better patient management and personalized treatment plans.

Benefits of this technology:

* Enables early identification of individuals at a higher risk of developing a breast late effect (BLE) after radiotherapy.
* Facilitates targeted interventions and preventive measures to reduce the risk of BLE and improve patient outcomes.
* Provides healthcare professionals with a more objective and reliable tool for assessing the risk of BLE, leading to better treatment planning and decision-making.


==Original Abstract Submitted==

the present invention is drawn to a new diagnosis method and a calculator for predicting the risk of developing a breast late effect (ble), which is defined as atrophic skin, telangiectasia, induration (fibrosis), necrosis or ulceration, in a subject after radiotherapy (rt), by using radiation induced late effect using t-lymphocyte apoptosis (rila) and clinical parameters. the invention is also drawn to diagnosis kits for the implementation of the method and a nomogram.



[[Category:G16H50/30]]
[[Category:G16H20/40]]
[[Category:G01N33/68]]